60 Degrees Pharmaceuticals (SXTP) Change in Receivables (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Change in Receivables of -$173808.0 for Q1 2026, down 11725.95% year-over-year from N/an in Q1 2025, and down 5.73% quarter-over-quarter from -$164392.0 in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) Change in Receivables (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Change in Receivables for 5 consecutive years, with -$173808.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Receivables fell 11725.95% year-over-year to -$173808.0; the TTM figure through Mar 2026 stood at -$152407.0 (down 188.6% YoY), while the FY2025 annual figure was $22896.0, down 91.04% from the prior year.
- Change in Receivables eased to -$173808.0 in Q1 2026 per SXTP's latest filing, from -$164392.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $379002.0 in Q3 2025 and bottomed at -$193209.0 in Q2 2025.
- Historically, Change in Receivables has averaged $19033.6 across 5 years, with a median of $27452.0 in 2024.
- Annual changes were most pronounced in 2025 — Change in Receivables jumped 1280.6% — and 2026, when it sank 11725.95%.
- 60 Degrees Pharmaceuticals' Change in Receivables stood at -$149076.0 in 2022, then jumped by 162.6% to $93323.0 in 2023, then soared by 74.58% to $162926.0 in 2024, then sank by 200.9% to -$164392.0 in 2025, then decreased by 5.73% to -$173808.0 in 2026.
- Business Quant data shows SXTP's Change in Receivables at -$173808.0 in Q1 2026, -$164392.0 in Q4 2025, and $379002.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | 231,204.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -173,808.00 |
| Mar 31, 2026 | -173,808.00 |
| Dec 31, 2025 | -164,392.00 |
| Dec 31, 2025 | -164,392.00 |
| Sep 30, 2025 | 379,002.00 |
| Sep 30, 2025 | 379,002.00 |
| Jun 30, 2025 | -193,209.00 |
| Jun 30, 2025 | -193,209.00 |
| Mar 31, 2025 | 1,495.00 |
| Mar 31, 2025 | 1,495.00 |
| Dec 31, 2024 | 162,926.00 |
| Dec 31, 2024 | 162,926.00 |
| Sep 30, 2024 | 27,452.00 |
| Sep 30, 2024 | 27,452.00 |
| Jun 30, 2024 | -19,850.00 |
| Jun 30, 2024 | -19,850.00 |
| Mar 31, 2024 | 84,888.00 |
| Mar 31, 2024 | 84,888.00 |
| Dec 31, 2023 | 93,323.00 |
| Dec 31, 2023 | 93,323.00 |